Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | GRM5 | P41594 | 7/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20177032 | 0.80 | RXFP1 (0.57) | MEN1KMT2AGRM5NPC1RAB9A | |
| SCHEMBL21579395 | 0.77 | NPC1 (0.50) | MEN1KMT2AGRM5CYP1A2CYP2C9 | |
| SCHEMBL21579348 | 0.76 | NPC1 (0.62) | MEN1KMT2AGRM5CYP1A2NPC1 | |
| SCHEMBL3631785 | 0.73 | MEN1 (0.50) | MEN1KMT2AGRM5CYP1A2CYP2C9 | |
| SCHEMBL14659262 | 0.73 | SMN1; SMN2 (0.55) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL14659580 | 0.72 | ATR (0.53) | MEN1KMT2ACYP1A2NPC1RAB9A | |
| SCHEMBL5630272 | 0.72 | KDM4E (0.61) | MEN1KMT2AGRM5CYP1A2CYP2C9 | |
| SCHEMBL5630269 | 0.72 | FFAR2 (0.51) | MEN1KMT2AGRM5CYP1A2CYP2C9 | |
| SCHEMBL21395183 | 0.71 | NPC1 (0.47) | MEN1KMT2ANPC1RAB9ARXFP1 | |
| SCHEMBL20177031 | 0.69 | GRM5 (0.49) | GRM5ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2019-11-21 | — | — | US | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352276-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, CNKSR1 | MEN1 3821/4885KMT2A 1689/4885GRM5 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.